New data on potential therapy for early PD reported

At MDS 2020, researchers presented findings from part 1 of a two-part trial of prasinezumab in patients with early Parkinson’s disease (PD).

Prasinezumab is a humanized monoclonal antibody designed to target α‐synuclein, with the aim of reducing neuronal toxicity and blocking the spread of pathogenic α‐synuclein aggregates.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.